HANLING ZHENG: Open Payments
NPI 1730847062 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 18 payments from 7 companies in 2025. Trend: 2023 $76 · 2024 $44 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $86 |
| Janssen Pharmaceuticals, Inc | 2 | $80 |
| Alkermes, Inc. | 3 | $58 |
| ABBVIE INC. | 3 | $52 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: CAPLYTA, INVEGA SUSTENNA, REXULTI, VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, COBENFY, TRINTELLIX.
Industry payments across PA — which companies pay providers there.
